- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Thank you
XVIVO has received market approval from the FDA for STEEN Solution™ and XPS™.
After several years of product development in close collaboration with experienced transplantation centers, and subsequent comprehensive clinical studies in Canada and the USA to verify both product and patient safety, XPS™ and STEEN Solution™ have received FDA approval as a Humanitarian Use Device (HUD). The work on obtaining market approval from the FDA was started in 2009 and an HDE application was submitted in July 2012. During the process, clinical studies have been carried out to demonstrate product and patient safety, and in March 2014 the FDA’s Advisory Panel voted unanimously that XPS™ and STEEN Solution™ meet the requirements for HDE approval. After yesterday’s approval, the products may now be sold in the American market, and together will be labeled for the warm perfusion of initially unacceptable donated lungs.
EVLP with STEEN Solution™ has been used in more than 300 lung transplantations at almost 30 clinics, in Vienna, Paris, Toronto and elsewhere, and has displayed stable results there, similar to those that XVIVO Perfusion published from the American NOVEL study (see press release dated March 21, 2014).
“It is a breakthrough for XVIVO that we have now received approval from the FDA and can initiate sales of STEEN Solution™ and XPS™ in the American market after a time-consuming and comprehensive process with high patient and product safety requirements. The XPS™ machine and STEEN Solution™ mean that XVIVO now has a clinically proven method that is both CE marked and approved by the FDA. This method allows more lungs to be used for transplantation, which will potentially enable more patients with severe lung disease to achieve a greater quality of life as well as a longer life,” says Dr. Magnus Nilsson, CEO of XVIVO Perfusion AB.
August 13, 2014
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59, email@example.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on August 13, 2014 at 8:30 a.m.